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Abstract 
Filgotinib is a selective JAK1 (Janus kinase) inhibitor, showed efficacy in patients suffering from moderate-
to-severe rheumatoid arthritis. In this paper, we present the data on the development and validation of a 
sensitive, selective and high-throughput LC-MS/MS (liquid chromatography with tandem mass 
spectrometry) method for the quantitation of filgotinib from rat dried blood spot (DBS) cards. To the DBS 
disc cards, 0.2 % formic acid enriched with internal standard (IS) was added and sonicated. Thereafter the 
extraction of filgotinib and the IS (tofacitinib) was accomplished using ethyl acetate as an extraction 
solvent. The resolution of filgotinib and the IS was achieved on a Gemini C18 column with an isocratic 
mobile phase, which is a mixture of 0.2 % formic acid:acetonitrile (20:80, v/v) at a flow-rate of 0.9 mL/min. 
The total run time was 2.90 min and the retention time of filgotinib and the IS was ~1.31 and 0.89 min, 
respectively. Filgotinib and the IS were analyzed using positive ion scan mode and parent-daughter mass to 
charge ion (m/z) transition of 426.3291.3 and m/z 313.2149.2, respectively, for quantitation. The 
calibration range was 1.37-1937 ng/mL. No matrix effect and carry over were observed. All the validation 
parameters met the acceptance criteria. The validated method has been applied to a pharmacokinetic 
study in rats. A good correlation between DBS and plasma concentrations for filgotinib was observed. 
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Introduction 
Rheumatoid arthritis is a chronic autoimmune inflammatory disease with a prevalence of 1-2 % of the 
world population. Rheumatoid arthritis primarily affects peripheral joints and subsequently damages the 
synovial tissue and cartilage damage [1]. Although disease-modifying anti-rheumatic drugs (DMARDs: 
methotrexate, sulfasalazine, leflunomide etc) and biologic DMARDs (etanercept, adalimumab etc.) are 
available as first-line drugs due to their low therapeutic benefit and severe side effects they cannot be used 
for long-treatment [2]. To overcome these drawbacks, Janus kinase (JAK)/signal transducer and activator of 
the transcription (STAT) signal pathway has been identified as one of the new therapeutic targets to treat 
rheumatoid arthritis. JAK-STAT pathway plays a critical role in the downstream signaling of cytokines. The 
inhibition of JAKs is an attractive therapeutic target to treat rheumatoid arthritis [3]. Tofacitinib and 
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baricitinib are the pan-JAK inhibitors (JAK1/JAK3) approved for the treatment of moderate to severe 
rheumatoid arthritis but they showed dose-related toxicities [4]. Recent findings suggest that selective 
inhibition of JAK1 might reduce the toxicity without a significant detriment to efficacy [2,3]. Filgotinib 
(Figure 1; GLPG0634), is a selective JAK1 inhibitor (IC50: 629 nM) with 30-fold selectivity over JAK2 [5]. It 
has shown dose-dependent reduction of disease progression in a collagen-induced arthritis model post oral 
administration in rodents [5]. In Phase-3 clinical trials, filgotinib was well tolerated, showed efficacy and 
was found to be safe in rheumatoid arthritis patients, when it was administered as monotherapy at 100 or 
200 mg, once daily or with methotrexate [6]. Filgotinib is currently being filed in the US and Japan to treat 
the patients suffering from moderate-to-severe rheumatoid arthritis [7,8].  
 
 
Filgotinib Tofacitinib (IS; internal standard) 
Figure 1. Structural representation of filgotinib and tofacitinib (IS). 
To date, two LC-MS/MS (liquid chromatography with tandem mass spectrometry) methods were 
reported for the quantification of filgotinib. The first method, reported by Namuor et al. (2015) employed 
solid-phase extraction method for the quantitation of filgotinib and its active metabolite from Phase-I 
study plasma samples [100 µL plasma sample was spiked with 20 µL of deuterated filgotinib (125 ng/mL) as 
an internal standard]. The reported lower limit of quantification (LLOQ) was 3.00 ng/mL. However, full 
details on chromatography, mass spectrometer conditions and validation parameters were not reported 
[9]. Very recently, Dixit et al. (2020) reported a validated LC-MS/MS method for the quantification of 
filgotinib. The authors have attained an LLOQ of 0.78 ng/mL with 50 µL rat plasma. Plasma samples were 
processed using ethyl acetate as an extraction solvent [10].  
Dried blood spot (DBS) methodology has seen significant progress during recent times in the 
quantitative analysis of various drugs [11-16]. DBS offers several advantages over traditional sampling 
(plasma/blood/serum) techniques such as reduction of commercial costs for laboratory equipment, 
convenience in collection, reduction in collection of blood volume, no requirements for trained 
phlebotomist, ease of sample handling/storage/shipping, safety in handling, less time in processing and 
increase in throughput etc. It is anticipated that much clinical development and therapeutic drug 
monitoring programs in the future may switch to DBS technique to characterize the pharmacokinetic data.  
To the best of our knowledge, there is no DBS method reported for the quantitation of filgotinib. In this 
paper, we report the development and validation of an LC-MS/MS method for the quantitation of filgotinib 
on rat DBS. The applicability of the validated method was shown in a rat pharmacokinetic study. Excellent 
correlation was observed between DBS versus plasma filgotinib concentrations, indicating that the DBS 
method can be used as an alternative for plasma sampling for pharmacokinetic analysis. 
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Materials and methods  
Materials 
Filgotinib (purity: >95 %) was purchased from Angene International Limited, Tsuen Wan, Hong Kong. 
Tofacitinib (IS; purity: 98 %) was purchased from Sigma-Aldrich (St. Louis, USA). HPLC grade acetonitrile and 
methanol were purchased from J.T. Baker, PA, USA. Analytical grade formic acid was purchased from S.D 
Fine Chemicals, Mumbai, India. All other chemicals and reagents were of analytical grade and used without 
further purification. The control Sprague Dawley rat blood was procured from Animal House, Jubilant 
Biosys, Bangalore. 
Liquid chromatography and mass spectrometry conditions  
We used the similar chromatographic conditions that we previously reported [10]. In brief, a Gemini 
C18 (100 × 4.6 mm, 3 µm) column maintained at ambient room temperature along with an isocratic mobile 
phase (0.2 % formic acid in Milli-Q water:acetonitrile, 20:80, v/v) at a flow-rate of 0.9 mL/min was used for 
separation of filgotinib and the IS. The injection volume was 5.0 µL. Under these optimized conditions the 
retention times were 1.31 and 0.89 min, for filgotinib and the IS, respectively with a total run time of 2.90 
min. The LC was coupled to a Sciex 4000 mass spectrometer controlled by Sciex Analyst 1.6.2 software. The 
MS was equipped with electro-spray ionization and operated in the multiple reaction monitoring (MRM) 
mode for the quantitation. Ionization was conducted by applying a voltage of 5500 V, and the source 
temperature was set at 550 °C. The gas settings were as follows - curtain gas: 35 psi, GS1: 50 psi, GS2: 55 
psi and CAD: 8.0 psi. The compound parameters declustering potential, entrance potential, collision 
energy, and collision cell exit potential were set at 91, 10, 40, and 10 V for filgotinib and 100, 10, 41, and 12 
V for the IS. The mass transitions m/z (precursor ionproduct ion) 426.3291.3 and 313.2149.2 were 
monitored for filgotinib and the IS, respectively. Quadrupole Q1 and Q3 were set on the unit resolution. 
Dwell time was 150 ms. 
Preparation of stock solutions and standard samples 
Two separate primary stock solutions of filgotinib were prepared at 1670 g/mL in DMSO. Appropriate 
secondary and working stocks of filgotinib were prepared from primary stock by successive dilution of 
primary stock with methanol:water (80:20, v/v) to prepare the calibration curve (CC) and quality controls 
(QCs). The IS primary stock solution was made in DMSO at a concentration of 1000 µg/mL, which was 
diluted with methanol to 500 ng/mL and subsequently used as IS working stock solution. The primary stock 
solutions of filgotinib and the IS were stored at -20 °C, which were found to be stable for 50 days. Working 
stock solutions were stored at 4 °C for 25 days.  
Blood spotting 
Freshly drawn rat blood was used to prepare the DBS cards. With the help of a calibrated pipette, 25 μL 
of the respective spiked CC/QC blood or whole blood collected from the pharmacokinetic study (post 
administration of filgotinib by intravenous and oral routes) was sampled on DBS card. Spiked cards were 
allowed to dry at ambient room temperature for 3 h and stored appropriately in a sealed bag with 
desiccant in a desiccator. 
DBS homogeneity 
The spot homogeneity was evaluated by punching out the disc from the periphery of the DBS. Blood 
spots at QC low and QC high level were prepared in triplicate. The obtained DBS discs were processed and 
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analyzed as described in the Sample Preparation section.  
DBS sample preparations  
Using a hole puncher (Harri-Micro-Punch®), 3 mm diameter disc was punched from the center of each 
DBS (FTA DMPK-C Card) card directly into micro-centrifuge tubes. To each micro-centrifuge tube, 200 µL of 
0.2 % formic acid enriched with 100 ng/mL of IS was added, thereafter the contents were vortex mixed for 
5 min (Thermomixer
®
, Eppendorf) and sonicated (Elmasonic S300 H) for 15 min at ambient room 
temperature. After sonication, to the same micro-centrifuge, 1.0 mL of ethyl acetate was added and the 
mixtures were vortexed further for 3 min. The samples were centrifuged at 14,000 rpm for 3 min. Clear 





,Kopkinton, MA, USA) at 50 °C. The residue was reconstituted with 200 µL of 0.2 % 
formic acid in acetonitrile and 150 µL clear supernatant was aliquoted into a HPLC vial and 5.0 µL was 
injected onto the column for LC-MS/MS analysis. 
Validation procedure 
The validation experiments were performed in accordance with the US Food and Drug Administration 
guideline [17]. Various parameters covered under validation are: selectivity, carry over (repetitive punching 
and auto-injector), recovery, matrix effect, linearity, precision, accuracy, stability (in-injector, 6 h at room 
temperature and 30-day long-term at -80 ± 10 °C) and incurred sample reanalysis.  
Influence of hematocrit 
Two different hematocrit (Hct) blood samples at 30 and 50 % were prepared at LQC and HQC by adding 
or removing the plasma to the rat blood. These samples (in quadruplicate at each QC) were analysed with 
calibrators prepared in blood at standard fixed 40 % Hct. The relative error of ±15 % and precision of ±15 % 
was considered acceptable. Hct value in rats ranged between 38-46 % (in-house data; measured using 
Mindray BC-5000Vet) and it is in line with reported values [18].  
Pharmacokinetic study in rats 
All the animal experiments were approved by Institutional Animal Ethical Committee 
(IAEC/JDC/2019/189R). Male Sprague Dawley rats (n=8) were procured from Vivo Biotech, Hyderabad, 
India. The animals were housed in Jubilant Biosys animal house facility in a temperature (22 ± 2 °C) and 
humidity (30-70 %) controlled room (15 air changes/hour) with a 12:12 h light:dark cycles, had free access 
to rodent feed (Altromin Spezialfutter GmbH & Co. KG., Im Seelenkamp 20, D-32791, Lage, Germany) and 
water for one week before using for experimental purpose. Following ~12 h fast (during the fasting period 
animals had free access to water) animals were divided into two groups having four rats in each group. 
Group I animals (205-210) received filgotinib orally as a suspension formulation (prepared using Tween-80 
and 0.5 % methyl cellulose) at 10 mg/kg (strength: 1.0 mg/mL; dose volume: 10 mL/kg), whereas Group II 
animals (215-225 g) received filgotinib intravenously (5 % DMSO, 5 % Solutol:absolute alcohol (1:1, v/v) and 
90 % of normal saline; strength: 0.5 mg/ml; dose volume: 4 ml/kg) at 2.0 mg/kg dose. Post-dosing serial 
blood samples (50 µL) were collected through retro-orbital plexus into polypropylene tubes containing 
K2.EDTA solution as an anti-coagulant at 0.25, 0.5, 1, 2, 4, 8, 10, 12 and 24 h (for oral study) and 0.083, 
0.25, 0.5, 1, 2, 4, 8 and 24 h (for intravenous study). Animals were allowed to access feed 2 h post-dosing. 
Pharmacokinetic analysis 
Blood concentration-time data of filgotinib was analyzed by non-compartmental method and the 
ADMET & DMPK 8(2) (2020) 139-148 DBS method for filgotinib quantitation 
doi: http://dx.doi.org/10.5599/admet.796 143 
relevant pharmacokinetic parameters namely AUC0- (area under the blood concentration-time curve from 
time zero to infinite time), C0 (extrapolated blood concentration at time zero), Cmax (maximum blood 
concentration), Tmax (time to reach Cmax), Vd (volume of distribution), CL (clearance) and t½ (terminal half-
life) were calculated using Phoenix WinNonlin software (version 8.1; Pharsight Corporation, Mountain 
View, CA). Absolute oral bioavailability (F) was calculated using this formula [Dose (i.v.) × AUC(0-)oral / Dose 
(oral) × AUC(0-)i.v.] × 100. 
Results and discussion  
Method development  
The objective of this work was to develop a sensitive and rugged DBS method for the quantification of 
filgotinib in rat blood and subsequently show the correlation with previously developed method [10] in a 
pharmacokinetics study so that DBS method can be used as an alternative method to measure the 
filgotinib concentrations. Previously reported LC-MS/MS conditions were utilized for this method [10].  
Since chromatography and mass spectrometric conditions were optimized, to obtain better sensitivity 
extraction optimization was done with various extraction solvents namely acetonitrile, methanol, ethyl 
acetate, acidified methanol/acetonitrile, mixture of water and methanol/acetonitrile, pre-treatment of DBS 
discs with formic acid followed by extraction with methanol/acetonitrile/ethyl acetate.  
Method validation parameters 
Recovery 
None of the single organic solvents and pure water gave good recovery of filgotinib from the DBS discs. 
The recovery with ethyl acetate, water and methanol/acetonitrile was 5, 39 and 43 %, respectively. With 
methanol/acetonitrile:water 50:50 and 20:80, the recovery was found to be 30 and 43 %, respectively. In 
order to improve the recovery, the DBS discs were pre-treated with 0.2 % formic acid and extracted with 
ethyl acetate. This process helped to attain the recovery up to 62 %. The mean ± S.D recovery of filgotinib 
at LQC and HQC was found to be 62.4 ± 8.39 and 64.2 ± 4.26 %, respectively. The recovery of the IS was 
95.2 ± 4.85 %.  
Matrix effect 
The mean absolute matrix effect for filgotinib on rat DBS cards at LQC and HQC was found to be 0.81 ± 
0.08 and 0.83 ± 0.08 %, respectively. The matrix effect for the IS was 0.97 ± 0.05 % (at 100 ng/mL). These 
results indicate that the minimal matrix effect did not obscure the quantification of on filgotinib and the IS 
from rat DBS cards.  
Selectivity and carry over 
Figures 2a,b,c show chromatograms for the blank rat DBS cards (free of analyte and the IS;  Figure 2a), 
blank rat DBS cards spiked with filgotinib at LLOQ and the IS (Figure 2b) and an in vivo blood sample 
obtained at 0.25 h after oral administration of filgotinib along with the IS (Figure 2c). There was no carry-
over produced by the highest calibration sample on the following injected blank DBS extract sample. 
Additionally, no DBS-specific device-oriented carry-over was noted.  








Figure 2. Typical MRM chromatograms of filgotinib (left panel) and the IS (right panel) in (a) rat blank DBS 
card (b) rat blank DBS card spiked with filgotinib at LLOQ (1.37 ng/mL) and the IS (c) a 0.25 h in vivo plasma 
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Figure 3. Bland-Altman plot showing the incurred sample re-analysis data for filgotinib on DBS. 
Calibration curve 
The calibration curve was constructed in the linear range using eight calibrators 1.34, 2.67, 14.7, 26.7, 
400, 801, 1603 and 1937 ng/mL. The typical regression equation for calibration curve was y = 0.000849 x + 
0.00127. The correlation coefficient (r) average regression (n=4) was found to be >0.9966 for filgotinib. The 
lowest concentration with the RSD <20 % was taken as LLOQ and was found to be 1.37 ng/mL. The 
accuracy observed for the mean of back-calculated concentrations for four calibration curves for filgotinib 
was within 95.9-110 %; while the precision (CV) values ranged from 3.87-7.94 %. 
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Accuracy and precision 
Accuracy and precision data for intra- and inter-day DBS samples for filgotinib is presented in Table 1. 
The assay values on both the occasions (intra- and inter-day) were found to be within the accepted variable 
limits.  
Stability 
The predicted concentrations for filgotinib at 4.01 and 1736 ng/mL samples deviated within ±15 % of 
the fresh sample concentrations in a battery of stability tests: bench-top (6 h), in-injector (21 h) and freezer 
stability at -80  10 °C for at least for 30 days (Table 2). The results were found to be within the assay 
variability limits during the entire process.  











Mean ± S.D 1.34 ± 0.10 4.30 ± 0.45 1136 ± 73.3 1715 ± 124 
Precision (%RSD) 7.38 10.4 6.46 7.23 
Accuracy (%RE) 1.00 1.07 1.06 0.99 
Inter-day (n=24) 
Mean ± S.D 1.33 ± 0.15 3.94 ± 0.44  1064 ± 96.8 1663 ± 128 
Precision (%RSD) 11.0 11.2 9.09 7.71 
Accuracy (%RE) 1.00 0.98 1.00 0.96 
RSD: relative standard deviation (SD 100/Mean)  
RE: relative error (measured value/actual value) 
Table 2. Stability data of filgotinib quality controls in rat plasma 
 RSD: relative standard deviation (SD 100/Mean) 
 RE: relative error (measured value/actual value) 
 
Incurred samples reanalysis (ISR) 
As per guidance [17] around 10 % of the study samples should be selected for ISR if the total sample 
size is less than 1000. In this validation a total of 20 samples were chosen for ISR from the oral and 
intravenous rat pharmacokinetic studies. From oral arm samples near Cmax (0.5 h) and elimination phase 
(4 h and 24 h) were selected. However, for intravenous arm representative samples at 0.083, 2 and 8 h 
time points were selected.  Figure 3 shows the comparison of ISR values versus original values using Bland-






Bench-top for 6 h 
(n=6) 
Long-term  
30 days at -80 °C 
(n=6) 
In-injector for 21 h 
(n=6) 
% RE %RSD % RE %RSD % RE %RSD 
4.01 0.96 11.1 0.97 15.1 0.91 5.99 
1736 0.88 4.09 0.96 6.04 0.88 2.39 
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Hematocrit effect  
Hematocrit (Hct) has a significant effect on the viscosity of the blood, which influences the flux and 
diffusion properties of the blood through DBS card used for sample collection. It can directly affect the 
accuracy of the analysis in DBS samples. The reported blood-to-plasma ratio for filgotinib was 1.22 [19] 
indicating an almost equal plasma and red blood cell distribution. The measured filgotinib concentrations 
were compared with the results obtained from DBS samples are given in Table 3, indicating that Hct had no 
significant influence on the filgotinib concentration.  











30 3.95 ± 0.19 0.98 4.81 
50 3.90 ± 0.24 0.97 6.29 
1736 
30 1664 ± 80.4 0.95 4.83 
50 1786 ± 88.7 1.02 4.96 
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Figure 4. a) mean plasma concentration-time profiles of filgotinib in rat blood and plasma following 
intravenous administration of filgotinib; b) mean plasma concentration-time profiles of filgotinib in rat blood 
and plasma following oral administration of filgotinib. 
Pharmacokinetic study 
The sensitivity of the present DBS method was found to be sufficient for accurately characterizing the 
pharmacokinetics of filgotinib by oral and intravenous routes in rats. To assure acceptance of study sample 
analytical runs, at least two-thirds of the QC samples had to be within ±15 % accuracy, with at least half of 
the QC samples at each concentration meeting these criteria. Results indicated that QCs met the 
acceptance criteria. Figures 4a and 4b show the mean blood concentration versus time for filgotinib post 
administration of intravenous and oral route, respectively in rats. The pharmacokinetic parameters are 
summarized in Table 4 along with previously reported pharmacokinetic parameters by Dixit et al. [10]. 
Filgotinib was quantifiable up to 24 h post intravenous and oral administration to rats. Following 
intravenous administration at 2.0 mg/kg, the plasma concentrations decreased mono-exponentially. 
Filgotinib exhibited moderate clearance (Cl) of 18.7 ± 1.86 mL/min/kg, which is ~3-fold lower than hepatic 
blood flow (55 mL/min/kg) and volume of distribution (Vd) was 4.17 ± 0.33 L/kg in rats. The terminal half-
life was found to be 3.52 ± 0.23 h. Following oral administration filgotinib maximum plasma concentrations 
(Cmax: 804 ± 78.4 ng/mL) attained at 0.50 ± 0.00 h (Tmax) in all rats suggesting that filgotinib has a rapid 
a) b) 
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absorption from the gastrointestinal tract. The AUC0- (area under the plasma concentration-time curve 
from time zero to infinity) was found to be 3722 ± 329 and 1801 ± 188 ngh/mL, by oral and intravenous 
routes, respectively. The terminal half-life (t½) determined after oral administration was 4.87 ± 0.45 h. The 
absolute oral bioavailability for filgotinib in rats at 10 mg/kg was 42.5 %. 
Table 4. Pharmacokinetic parameters for filgotinib in rats following oral and intravenous 
administration  
PK parameters  Oral Intravenous 
Dose (mg/kg) 10 2.0 
AUC(0-) (ng  h/ml) 
3722 ± 329 
 (3475 ± 547) 
1801 ± 188 
(1912 ± 123) 
Cmax/C0 (ng/ml) 
804 ± 78.4  
(802 ± 149) 
1602 ± 55.5  
(1767 ± 128) 
Tmax (h) 
0.50 ± 0.00  
(0.50 ± 0.00)  
--- 
T1/2 (h) 
4.87 ± 0.45  
(4.72 ± 0.24) 
3.52 ± 0.23 
(3.56 ± 0.30) 
CL (ml/min/kg) --- 
18.7 ± 1.86  
(17.4 ± 1.08) 
Vd (L/kg) --- 
4.17 ± 0.33 





 The values in parentheses are reported by Dixit et al. (2020) [10]. 
In Figures 4a and 4b the blood versus time concentration profiles of filgotinib obtained from intravenous 
and oral routes in rats were presented along with plasma versus time concentration profiles reported 
earlier by us [10] showed excellent correlation (R2 > 0.99). This indicates that DBS can be used as an 
alternative strategy for determination of filgotinib circulatory concentration in a pharmacokinetic study. To 
the best of our knowledge, to date there is no comparison between plasma and whole blood for filgotinib. 
Our study demonstrated that DBS is a promising alternative to plasma sampling for filgotinib in rheumatoid 
arthritis patients especially with elderly patients in remote or resource-limited settings or immobile 
patients. 
Conclusions 
In summary, a simple and rapid method using LC-MS/MS for the determination of filgotinib in rat blood 
using DBS cards was developed and validated as per US FDA regulatory guideline. The validated method 
suitability was shown in a rat pharmacokinetic study.  
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